On Friday, July 29th, the FDA issued a final guidance document entitled “General Wellness: Policy for Low Risk Devices,” which clarifies FDA’s Center for Devices and Radiological Health’s (CDRH’s) compliance policy for low-risk products that promote a healthy lifestyle. Read about this policy below, or get in touch with our experts for additional guidance.
CDRH will not examine low-risk general wellness products to determine whether or not they are considered devices under the Federal Food, Drug, & Cosmetic (FD&C) Act. In addition, for those products that are considered to be devices, FDA notes that it will not assess whether or not they comply with the regulatory requirements of the FD&C Act.
FDA notes that “there are instances where certain general wellness products, as discussed in this guidance, do not meet the definition of a device under section 201(h) of the FD&C Act and therefore are not subject to the FD&C Act’s regulatory requirements for devices.” Furthermore, FDA clarifies that products included under the general wellness policy of FDA’s guidance have not necessarily been shown to be safe and/or effective for its intended use.
According to the guidance document, a general wellness product either:
FDA notes that if the product has an intended use that is not limited to the above criteria, this guidance does not apply.
“The first category of general wellness intended uses involve claims about sustaining or offering general improvement to functions associated with a general state of health that do not make any reference to diseases or conditions.” This includes claims relating to:
Examples of these types of general wellness claims include, but are not limited to, the following:
For a full list of examples of this category of general wellness claims, view FDA’s full guidance document.
The second category of general wellness intended uses involves those claims that “relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions.” This category of claims is split into two subcategories, which include:
These types of claims should be made only when it well understood and generally accepted that healthy lifestyle choices may reduce the risk or impact of a chronic disease or medical condition.
CDRH provides a list of examples of these types of claims in its guidance document.
The policy outlined in FDA’s recent guidance document applies only to low-risk general wellness products. In determining whether or not a product is low-risk, the following questions should be considered:
If the answer to any of these questions is “yes,” then the product is not considered to be low-risk, and thus is not exempt from FDA’s regulations.
When determining a product’s risk, FDA also recommends considering whether or not CDRH actively regulates products of the same type as the product in question, which should help determine whether or not the product is considered to be low-risk.
Additional information on determining risk and a list of examples of low-risk general wellness devices is available in FDA’s full guidance document.
Are you in the process of developing an FDA-regulated product? We can help ensure that your product is compliant with all regulations, helping you obtain FDA approval faster and easier. To learn more about our services and how we can help you, contact us today.
August 8, 2016
On, Tuesday, June 11th, 2019, the FDA issued a final guidance document entitled “Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems.” The guidance was published less...
August 8, 2016
On Thursday, March 7th, FDA published a revised draft guidance, updating its nonproprietary naming convention for biological products licensed under section 351 of the Public Health Service Act (PHS...
August 8, 2016
On February 2, 2016, the FDA’s Center for Biologics Evaluation and Research (CBER) published its annual invitation for biologics facilities to participate in the Regulatory Site Visit Training...